November 2024
FDA Panel Raises Safety Concerns Over AstraZeneca’s Anticoagulant Reversal Drug Andexxa
AstraZeneca, Andexxa, FDA panel, anticoagulant reversal drug, safety concerns, full approval
Aizen Therapeutics Unveils AI-Driven ‘Mirror Peptide’ Platform to Revolutionize Drug Development
Aizen Therapeutics, Caltech spinout, AI-driven platform, mirror peptides, drug development, biologic medicine, cancer treatment
FDA’s Peter Marks Advocates for Open Dialogue on Vaccines Amid Controversy
FDA, Peter Marks, Vaccines, Open Dialogue, RFK Jr, HHS Nomination
Trump Nominates Surgeon Martin Makary for FDA Commissioner Amid Criticism of COVID Mandates
Trump, FDA, Martin Makary, COVID mandates, surgeon, nomination
Amgen Appoints Howard Chang as Senior Vice President of Research and Chief Scientific Officer
Howard Chang, Amgen, Chief Scientific Officer, Research, Biotechnology, Pharmaceutical Industry
Novartis Enhances Mid-Term Growth Projections Following Strategic Transformation
Novartis, mid-term guidance, growth projections, pharmaceutical industry, innovative medicines, pipeline development
CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy
CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends
Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval
Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen
Novartis CEO Reveals Strategic Pipeline Reduction by 40% Based on Data-Driven Insights
Novartis, clinical pipeline, data-driven decisions, pharmaceutical industry, strategic reduction
The Fallout of Research Misconduct: Implications for Neurodegenerative Disease Studies
Research misconduct, Neurodegenerative diseases, Eliezer Masliah, NIH investigations, Future of neurodegenerative research